Neogen Chemicals shares surged 6.73% to ₹2,456.95 following the successful completion of its qualified institutional placement (QIP) fund raise of ₹5,99,99,98,015, as reported by Business Standard. The strong market response reflects investor confidence in the company's growth prospects and the strategic use of proceeds for debt reduction and working capital requirements. The stock movement demonstrates positive market sentiment toward the company's ability to strengthen its balance sheet through this institutional fundraising initiative.
Neogen Chemicals Ltd. has successfully completed its qualified institutional placement (QIP) fund raise of ₹5,99,99,98,015, as reported by CNBC TV18 and Business Standard. The company closed the issue on September 16, 2026, allotting 26,60,753 equity shares to eligible qualified institutional buyers at an issue price of ₹2,255 per equity share. This price exceeded the set floor price of ₹2,189.73, indicating strong investor demand for the offering. The Fund-Raising Committee approved the final price and closure of the issue period on that date. According to the latest filing, the committee met on September 16, 2026, from 11:50 p.m. to 11:55 p.m. to approve the allotment. The final issue price was determined in consultation with the lead managers appointed for the issue.
Following the QIP allotment, Neogen Chemicals' paid-up equity share capital has increased to ₹30.04 crore, comprising 3,00,42,427 equity shares of ₹10 each from the previous ₹27.38 crore consisting of 2,73,81,674 equity shares of ₹10 each, according to the exchange filing. The QIP issue was open from September 10 to September 16, 2026, providing institutional investors with a structured opportunity to participate in the company's growth story. The price includes a premium of ₹2,245 per share over the face value of ₹10. The dilution represents approximately 9.71% relative to the pre-issue share capital, with existing shareholders' proportionate ownership decreasing commensurately unless they hold shares in equivalent proportion through the new allottees. The newly allotted shares will be listed on both BSE and NSE and carry identical dividend and voting rights as existing shares from the date of allotment.
Several prominent institutional investors participated in the QIP, with SBI Life Insurance receiving 13.33% of the equity shares offered, followed by Abu Dhabi Investment Authority with 5.33%. Other significant participants included ICICI Prudential Multi Cap Fund with 8.33%, ICICI Prudential Mid Cap Fund with 2.67%, and ICICI Prudential Commodities Fund with 2.33%. Among allottees receiving more than 5%, SBI Life Insurance Co. Ltd received 3,54,768 shares (13.33%), while Abu Dhabi Investment Authority was allotted 1,41,907 shares (5.33%). The equity shares allotted rank pari passu with existing equity shares in all respects, including dividend and voting rights. Other significant investors include Invesco India Small Cap Fund with 11.90%, Mirae Asset funds, WhiteOak Capital funds, and Axis Mutual Fund schemes.
The company plans to utilize the net proceeds from the QIP for repayment/pre-payment, in full or part, of certain borrowings availed by the company; funding long-term working capital requirements; and general corporate purposes, as reported by Business Standard. This strategic approach demonstrates the company's focus on strengthening its balance sheet and improving financial flexibility. The fundraising comes alongside strong operational performance, with Neogen Chemicals recording 66.76% increase in consolidated net profit to ₹17.11 crore on a 34.04% rise in revenue to ₹250.29 crore in Q1 FY27 compared with Q1 FY27. Neogen Chemicals is one of India's leading manufacturers of bromine-based and lithium-based specialty chemicals, with product offerings comprising organic as well as inorganic chemicals.
